Trucheck CTC Cancer Screening Test 循環腫瘤細胞篩查檢測 (乳癌)- Female Product Cover_v2-min
ApexHealth Lab image
ApexHealth lab equiment
Trucheck CTC Cancer Screening Test 循環腫瘤細胞篩查檢測 (乳癌)- Female Product Cover_v2-min
ApexHealth Lab image
ApexHealth lab equiment

Trucheck CTC Cancer Screening Test (FemmeSafe)

HK$18,500

A easy blood screening test with high accuracy and specificity for asymptomatic female.

  • Covering 4 female common cancers types: Breast cancer, Ovarian cancer, Uterine cancer, Cervical cancer
  • Requires only small blood sample. Non-invasive and no radiation, which safer than imaging tests
  • Detects cancer risk in more early stage than traditional MRI and other blood marker
  • 96% accuracy
  • Able for routine cancer screening
  • Report explanation by Doctor or Medical Professional
Category: Tags: , , , ,
#20231027 New Trucheck CTC Promotion for Woman Logo 3

Trucheck CTC Cancer Screening Test (FemmeSafe)

A revolutionary blood test that enables early detection of multi-cancer for asymptomatic female with high sensitivity and specificity. Capable of detecting cancers at early / localized stages are crucial successful treatments, reduced treatment costs and improved survival rate.

Early cancer screening in women - Why is it important?
為甚麼進行早期乳癌篩查檢測_CN

A person’s risk of developing or dying from cancer is age-dependent. Based on the cancer statistics in 2020, about 1 in 4 men and 1 in 5 women will develop cancer before the age of 75.[1]

Cancer is now responsible for almost 1 in 6 deaths globally

[1] WHO

According to the data, the 5-year relative survival rate for cancer patients in stage 1 is 99.3%. However, for stage 3, it drops to 76.2%, and for stage 4, the 5-year relative survival rate is only 30%. [2]

[2] Cancer Patient Resource Centre

Cancer treatment costs reduce 2 to 4 times in early diagnosis

Advanced Technology for Trucheck Early Screening

Comprehensive Screening for Breast Cancer and other Common Female Cancer Risk at Early Stage

 

全球臨床研究案例 Individuals Tested & Validate​​

Individuals Tested & Validate

Over 96% Specificity and Accuracy

不會暴露於輻射

No exposure to radiation

非入侵性 Non Invasive

Non invasive

主要機構認可

Granted the coveted FDA Breakthrough Device Designation and CE-IVD certified

更早發現腫瘤風險

Detects cancer risk in more early stage than traditional blood markers

全球臨床研究案例​

Individuals Tested & Validate

特異度 準確度

Over 96% Specificity and Accuracy

不會暴露於輻射

No exposure to radiation

非入侵性

​Non invasive

主要機構認可

Granted the coveted FDA Breakthrough Device Designation and CE-IVD certified

更早發現腫瘤風險

Detects cancer risk in more early stage than traditional blood markers

Detect CTC for Cancer Signal in Early Stage for Higher Survival Rates

Metastasis dissemination is the main cause of cancer-related death

Circulating Tumor Cells (CTCs) gain ability to escape from primary tumor and travel through body via blood circulation, migrate to adjacent tissues or organs for metastasis and lead to the formation of new tumors.

CTCs as the biomarker for cancer screening can potentially identify cancer risk at an earlier stage

Comparison of blood-based multiple cancer screening test performance with cf-DNA (Other Multi-Cancer Screening Test) and Trucheck CTC Screening by different cancer stages. 

CTC test showed an overall higher sensitivity for Breast cancer detection across early stages (Stage 0 -2).

Overall 90%+ Sensitivity for Early Breast Cancer Screening
Covers 
Breast Cancer 
Ovarian Cancer 
Cervix Cancer 
Uterine Cancer 
4 major female cancer types
乳癌-min
Breast Cancer
子宮頸癌2
Cervix Cancer
卵巢癌-min
Ovarian Cancer
子宮內膜癌
Endometrial Cancer

Screening outclasses other similar cancer test in early stage

#20231027 New Trucheck CTC Promotion for Woman Logo-24

Compare to traditional MRI and blood markers more early, comprehensive Find out your cancer risk!

Who should get tested?

Be 40 years of age or older.

Individuals who have a family history of cancer.

甚麼人應進行檢測

Asymptomatic individuals who have a high risk in cancer.

Individuals who want to include this test in their yearly check-up.

Test Procedures

Order online and booking

Order online

or call us (852) 3979 3200 to make reservation

Go to our medical centre for testing

Go to our medical centre for the testing

Results ready in 3 weeks 

Professional medical report interpretation

Remarks

  1. No prior history of diagnosis or treatment of any cancer.
  2. Trucheck CTC Cancer Screening Test is a screening test and does not diagnose cancer. Follow up diagnostic testing is needed to confirm cancer.
  3. False positive and false negative results might do occur.
  4. The test is for reference only, and is not suitable for diagnostic and/or treatment use.

Terms and Conditions

  1. ApexHealth will contact the customer within 5 working days after successful payment. Customers can also call hotline at (852) 3979 3200 for booking.
  2. Customers must present their identity cards and on the appointment day.
  3. The service purchased is valid for two months (from the date of purchase) or it will be forfeited.
  4. **Offer cannot be used in conjunction with other promotional offers.
  5. No cancellation is acceptable once an order is confirmed.
  6. Service items may change without piror notice. In case of dispute, ApexHealth reserves all rights.
  7. For any enquiry, please call our customer services hotline at (852) 3979 3200.

Reference

  1. Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, Esener S, Fitzgerald RC, Gambhir SS, Kuhn P, Rebbeck TR, Balasubramanian S. Early detection of cancer. Science. 2022 Mar 18;375(6586):eaay9040. 
  2. Dillekås H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by metastases? Cancer Med. 2019 Sep;8(12):5574-5576.
  3. Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer. Nat Rev Clin Oncol. 2023 Jul;20(7):487-500.
  4. Gaya A, Crook T, Plowman N, et al. Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol. 2021;129(3):226-238.
  5. Crook T, Leonard R, Mokbel K, et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers (Basel). 2022;14(14):3341.
  6. Limaye S, Chowdhury S, Rohatgi N, et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023;12(8):9116-9127.
  7. Shao SH, Allen B, Clement J, Chung G, Gao J, Hubbell E, Liu MC, Swanton C, Tang WHW, Yimer H, Tummala M. Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. Tumori. 2023 Jun;109(3):335-341.
檢測項目

乳癌, 女性組合 (乳癌、卵巢癌、子宮頸癌、子宮內膜癌)